Bucket Shops

Update: Who’s Suing Cytodyn Now and What has Dr. Scott Kelly Been Doing About It? (CYDY)

Readers may recall that back at the end of April 2020, we discussed a number of lawsuits filed by former insiders against everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), and its klown krew of kreme de la kreme managers including The NaDDir* and Dr. Scott Kelly. Missed it? Catch up here.

You will find no mention in yesterday’s bizarre Cytodyn press release touting the utterly INsignificant “safety” results from the Phase 2 trial of wonder drug leronlimab in mild-to-moderate Covid patients, of any developments in the Delware case Alpha Venture Capital Partners LP v. Nader Z. Pourhassan (2020-0307-PAF). Nor will you find any mention of legal developments in The NaDDir’s bizarre rant on a paid stock pumping video put out on Youtube yesterday. Nor will you find any 8k filings from the company about developments in that case.

But there have been developments in the case, bad developments. Developments that Cytodyn likely does not want their retail shareholder base to learn about before the vote on authorizing 100mm more shares today, the 22nd of July.

(more…)

Quick Take – What Sort of Deceptive Nonsense is Cytodyn Spewing Now? (CYDY)

Finally, it is the 21st of July and the long awaited trial “results” from everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY) have arrived! Well, not really, because the company didn’t really announce any real results this morning (read more about that here). What The NaDDir* did announce was a collection of bizarre ramblings about wonder drug leronlimab‘s supposed safety from the Phase 2 trial of leronlimab in mild/moderate Covid patients (trial details here).

From this morning’s press release:

CYDY-Results1

The headline? Impressive Results….39% of patients in (the) placebo arm had SAEs as compared to only 14% of patients in (the) leronlimab arm.

More like impressive bullshit. Just a few lines later one can see that 6 out of 28 patients in the placebo arm, and 5 out of 56 patients in the leronlimab arm reported SAEs. That’s actually 21.4% and 8.9%.

Coming from the same klown krew who still can’t manage to file an acceptable BLA submission, is their failure to do simple math much of a surprise? Or was this a deliberate deception to make leronlimab somehow look more appealing in front of tomorrow’s shareholder meeting where management is hoping to get another 100mm shares authorized so the dilution can continue unimpeded.

*Spelled thusly for a double dose of that sweet sweet stock pimping.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Quick Take – Who’s Grossly Overexaggerating Cytodyn’s TAM Now? (CYDY)

Another day, another relentlessly “optimistic” piece of promotional garbage touting everyone’s favorite Pink Sheet Reverse Merger coronacrapper, Cytodyn (CYDY). Today it is this swill which trumpeted an outlandish TAM (Total Addressable Market) figure that whipped up retail investors on both sides of the Atlantic this morning, before reality began to seep back in. How outlandish? See for yourselves:

Cytodyn TAM (in their dreams)

Yes, $81bn, but that’s not all, maybe even $100bn!

Now for the sobering reality. Cytodyn has exactly zero approved drugs to sell. Zero. After much difficulty they have submitted a BLA to the FDA, to hopefully get their wonder drug, leronlimab, approved in early 2021. Guess that $81bn won’t come this year, if at all.

But even if they get their drug approved, the actual TAM is far far smaller. For you see, dear reader, leronlimab is what is known as a “CCR5 Entry Inhibitor“, and one that must be delivered by IV or injection. There already is a another CCR5 entry inhibitor on the market, known generically as maraviroc, or by its brand name, Selzentry. Unlike the hyped unapproved bullshit from Cytodyn, maraviroc is a convenient pill, available today.

Contrary to anything the long list of promoters, or even The Nadir, might claim, leronlimab is not a new class of medication, it is not a breakthrough, it is just another entry in an existing segment.

And how large is the Total Addressable Market for CCR5 Entry Inhibitors? Currently maraviroc has 100% of that market, and it was, for 2019 a paltry $88mm USD and SHRINKING.

TAM-Chart

Even if leronlimab magically captured 100% market share, $88mm is still only about 7/10ths of a percent of the supposed $12bn HIV TAM. Good luck with that $81bn!

Oh, and coronavirus? If CCR5 entry inhibition had anything to do with Coronavirus, Doctors world-wide would already be using maraviroc. Surprise! They aren’t. 

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take: Who ALSO Sold Cytodyn Stock Last Week? (CYDY)

After the bell last night a Form 4 filing (see last week’s infamous Form 144 filing here) was released concerning everybody’s favorite pink sheet bioturd, the Creme de la Creme of Coronacrappers, Cytodyn (CYDY).

ScottKelly

First the CEO Nader “The Nadir” Pourhassan dumped a bunch of stock starting on the 30th of April, with an absolutely insane explanation (more on that soon, but start here), then the CMO, Scott Kelly let loose 1.2mm shares on the 1st of May. Taking advantage of severe cases of Coronamania among stuck at home retail investors both in the USA and Germany seems to be the new normal among bioturds and their execs.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Who ELSE is Selling Cytodyne Stock Now? (CYDY)

After the bell today a Form 144 filing (get it here in the April 30 link) was released concerning everybody’s favorite pink sheet bioturd, Coronacrapper extraordinaire, Cytodyn (CYDY).

1175680 CytoDynInc NaderPourhassan 20200430

CYDY=144

Yes, CEO Nader “The Nadir” Pourhassan sold 4.8mm shares on 30 April, while telling the world the amazing wonders of Cytodyn‘s ancient one time AIDS-then cancer-now-coronavirus drug. Said the company that day:

(more…)

Who’s Selling Cytodyn Stock Now? (CYDY)

Last night, as April came to a close, pink sheet Coronacrap stock, Cytodyn (CYDY), a favorite of retail investors both in the USA and Germany (Freut mich), released an amended S3 filing with the SEC. (Catch up on Who’s Touting Cytodyn Now and Who’s Suing Cytodyn Now too)

This filing will allow for millions of shares to be dumped on the market. How many millions?

(more…)

Who’s Touting Cytodyn Now? (CYDY)

Pink sheet retail investor AIDS-turned-Cancer-turned-Coronacrap favorite Cytodyn (CYDY) has been quite the darling of the stuck-at-home newbie trader crowd lately. It seems not a day goes by without some form of stock promotion. And today, 28 April, is no exception.

Presenting an absolute howler of a puff piece on Seeking Alpha, entitled “Finding The Kink In COVID-19’s Armor – Preventing ARDS” by one Theodore Zucconi.

(more…)

Anyone remember Zika Diagnostics, Inc.? – (CODX)

While 2020 is clearly the year of the “Wuhan Flu”, just four years ago, in 2016, a different viral scourge was making headlines. We are discussing, of course, the Zika Virus. Unlike the current Coronavirus pandemic, Zika most certainly attacked children. Most notably crossing the placental barrier and destroying fetal brain tissue in the womb.

The first Zika fatality in the USA occurred in February 2016. As of early March 2016 there were nearly 200 cases in the United States.

In late August 2016, the city of Miami Beach begins closing off some areas to prevent the spread. Tourists, especially pregnant women, are especially worried. Stories of Zika spreading throughout the United States, of being sexually transmitted for months after infection, and more, move like wildfire across the interwebs.

But fear not, a small company with no revenue history, based in Salt Lake City, is ready to ease your fears, and maybe let you get rich at the same time! Introducing Zika Diagnostics, Inc. 

(more…)

Quick Take – Well Done Abeona (ABEO)

Today is a very special day friends, it marks an all time low for Steve Rouhandeh and Mark Ahn‘s reverse merger mega stinker Abeona Therapeutics (ABEO).

Steve, a well known stock promoter (see this great piece by Aaron Elstein here) somehow transitioned from hawking dot-bombs to bio-turds. Mark Ahn of Galena infamy hardly needs an introduction.

For those unfamiliar with their latest sinkhole, Abeona started life way back in 1974 as Chemex Corporation. In 1983 it became Chemex Pharmaceuticals. In 1996 it became Access Pharmaceuticals. In 2014 it became PlasmaTech Biopharmaceuticals, In 2015 it finally became Abeona. Here’s a stock chart going back as far as Bloomberg has data:

Abeo-LongTerm

Please note the all time low, $1.89 is today (23 August 2019), the all-time high was $218,000 back in 1981. That is impressive value destruction. Well done SCO (and Mark).

Always remember Maxim 1: ALL REVERSE MERGERS ARE SCAMS. ALL OF THEM. EVERY SINGLE ONE. IN ONE WAY OR ANOTHER.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

RE-UP From 2019: A Hazy Shade of Winter – Part 1 (TYME)

[This post contains thoughts about Tyme Technologies (TYME) from January 2019. Due to recent events, and its transformation from Cancercrapper to Coronacrapper it seems appropriate to re-examine it now, two years later. Fans of biocrap will recognize several names from fellow Coronacrapper Relief Therapeutics (RLFTF) as well.]

Back in March 2012 a wretched Siesta Key, FL shell company called Global Group Enterprises (GGET) was born out of the offices of Diane J. Harrison.

globalgroups1

Diane is well known among fans of small cap stock scams, and to the SEC. She has the rare honor of being one of the few lawyers ever chastised for their role in aiding, abetting, and perpetrating stock frauds.

The SEC’s complaint alleges that attorney Diane J. Harrison, Esq. and her husband, Michael J. Daniels, both of Palmetto, Florida, manufactured at least five microcap issuers with the undisclosed intent to sell them based on their status as public companies with purportedly unrestricted shares available for resale in the public markets. According to the complaint, Daniels and Harrison created the false appearance that the companies were pursuing specific business plans with independent management and shareholders by installing friends and family (including defendant Catherine A. Bradaick-Zolla of Sarasota, Florida, who also provided other assistance to the fraud) as purported officers and shareholders.

and that’s not all:

(more…)